The former pharma CEO, who at one point was head of two companies, was arrested in December on charges of securities fraud related to events earlier in his career. The charges were not related to the incident that made Shkreli a household name — his 5,000% price increase of a critical antiparasitic drug called Daraprim.

Shkreli was originally scheduled to appear in federal district court on Wednesday, but this change in lawyers could delay that hearing. In his letter, Asner wrote that the lawyers for all parties involved are looking into an alternative date the week of February 1.